Physician profile
Todd S Lefkowitz
NPI 1134362320
$3,295.29
in general payments reported to CMS, 2019-2025
13 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $507 · 2021: $322 · 2022: $369 · 2023: $240 · 2024: $85.20 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $752 · Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $751.96 |
| Food and Beverage | $683.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Motiva USA, LLC | $774.40 | 2025 | |
| Allergan, INC. | $748.61 | 2019-2022 | |
| Mentor Worldwide LLC | $583.99 | 2019-2024 | Mentor Memorygel Resterilizable Gel Sizer, Prolene |
| Kci USA, INC. | $283.21 | 2019-2022 | |
| Abbvie INC. | $185.71 | 2023-2025 | |
| Tela Bio, INC. | $168.11 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Musculoskeletal Transplant Foundation INC. | $153.94 | 2019-2021 | |
| Sientra, INC. | $153.25 | 2019-2021 | |
| Integra Lifesciences Corporation | $140.38 | 2023-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Pacira Pharmaceuticals Incorporated | $52.89 | 2023-2025 | Exparel |
| Baxter Healthcare | $18.73 | 2020 | |
| Axonics, INC. | $18.14 | 2023 | Axonics |
| Galderma Laboratories, L.P. | $13.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Lefkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.